Literature DB >> 19149603

CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions.

Eduardo Nunes Chini1.   

Abstract

CD38 is a multifunctional enzyme that uses nicotinamide adenine dinucleotide (NAD) as a substrate to generate second messengers. Recently, CD38 was also identified as one of the main cellular NADases in mammalian tissues and appears to regulate cellular levels of NAD in multiple tissues and cells. Due to the emerging role of NAD as a key molecule in multiple signaling pathways, and metabolic conditions it is imperative to determine the cellular mechanisms that regulate the synthesis and degradation of this nucleotide. In fact, recently it has been shown that NAD participates in multiple physiological processes such as insulin secretion, control of energy metabolism, neuronal and cardiac cell survival, airway constriction, asthma, aging and longevity. The discovery of CD38 as the main cellular NADase in mammalian tissues, and the characterization of its role on the control of cellular NAD levels indicate that CD38 may serve as a pharmacological target for multiple conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19149603      PMCID: PMC2883294          DOI: 10.2174/138161209787185788

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  79 in total

1.  Metabolism of cyclic ADP-ribose: Zinc is an endogenous modulator of the cyclase/NAD glycohydrolase ratio of a CD38-like enzyme from human seminal fluid.

Authors:  Weronika Zielinska; Hosana Barata; Eduardo N Chini
Journal:  Life Sci       Date:  2004-02-20       Impact factor: 5.037

Review 2.  Reconstructing eukaryotic NAD metabolism.

Authors:  Anthony Rongvaux; Fabienne Andris; Frédéric Van Gool; Oberdan Leo
Journal:  Bioessays       Date:  2003-07       Impact factor: 4.345

Review 3.  NAD+ surfaces again.

Authors:  Mathias Ziegler; Marc Niere
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

4.  Neuroscience. NAD to the rescue.

Authors:  Antonio Bedalov; Julian A Simon
Journal:  Science       Date:  2004-08-13       Impact factor: 47.728

5.  Structural determination of a cyclic metabolite of NAD+ with intracellular Ca2+-mobilizing activity.

Authors:  H C Lee; T F Walseth; G T Bratt; R N Hayes; D L Clapper
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

Review 6.  SIR2: the biochemical mechanism of NAD(+)-dependent protein deacetylation and ADP-ribosyl enzyme intermediates.

Authors:  Anthony A Sauve; Vern L Schramm
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

7.  The role of cyclic-ADP-ribose-signaling pathway in oxytocin-induced Ca2+ transients in human myometrium cells.

Authors:  Hosana Barata; Michael Thompson; Weronika Zielinska; Young S Han; Carlos B Mantilla; Yedatore S Prakash; Simone Feitoza; Gary Sieck; Eduardo N Chini
Journal:  Endocrinology       Date:  2003-10-16       Impact factor: 4.736

8.  Purification and characterization of a molluscan egg-specific NADase, a second-messenger enzyme.

Authors:  M R Hellmich; F Strumwasser
Journal:  Cell Regul       Date:  1991-03

9.  Pyridine nucleotide metabolites stimulate calcium release from sea urchin egg microsomes desensitized to inositol trisphosphate.

Authors:  D L Clapper; T F Walseth; P J Dargie; H C Lee
Journal:  J Biol Chem       Date:  1987-07-15       Impact factor: 5.157

10.  ADP-ribosyl cyclase: an enzyme that cyclizes NAD+ into a calcium-mobilizing metabolite.

Authors:  H C Lee; R Aarhus
Journal:  Cell Regul       Date:  1991-03
View more
  84 in total

1.  Polymorphic toxin systems: Comprehensive characterization of trafficking modes, processing, mechanisms of action, immunity and ecology using comparative genomics.

Authors:  Dapeng Zhang; Robson F de Souza; Vivek Anantharaman; Lakshminarayan M Iyer; L Aravind
Journal:  Biol Direct       Date:  2012-06-25       Impact factor: 4.540

2.  Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.

Authors:  Claudia C S Chini; Anatilde M Gonzalez Guerrico; Veronica Nin; Juliana Camacho-Pereira; Carlos Escande; Maria Thereza Barbosa; Eduardo N Chini
Journal:  Clin Cancer Res       Date:  2013-09-11       Impact factor: 12.531

3.  CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.

Authors:  Meisam Naeimi Kararoudi; Yuya Nagai; Ezgi Elmas; Marcelo de Souza Fernandes Pereira; Syed Abbas Ali; Philip Hollingsworth Imus; Darren Wethington; Ivan Marques Borrello; Dean Anthony Lee; Gabriel Ghiaur
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

4.  YCL047C/POF1 is a novel nicotinamide mononucleotide adenylyltransferase (NMNAT) in Saccharomyces cerevisiae.

Authors:  Michiko Kato; Su-Ju Lin
Journal:  J Biol Chem       Date:  2014-04-23       Impact factor: 5.157

Review 5.  Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies.

Authors:  Yi Zhu; Jiaqi Liu; Joun Park; Priyamvada Rai; Rong G Zhai
Journal:  Pharmacol Ther       Date:  2019-04-08       Impact factor: 12.310

6.  The dynamic regulation of NAD metabolism in mitochondria.

Authors:  Liana Roberts Stein; Shin-ichiro Imai
Journal:  Trends Endocrinol Metab       Date:  2012-07-21       Impact factor: 12.015

Review 7.  NAD and the aging process: Role in life, death and everything in between.

Authors:  Claudia C S Chini; Mariana G Tarragó; Eduardo N Chini
Journal:  Mol Cell Endocrinol       Date:  2016-11-05       Impact factor: 4.102

Review 8.  Regulation of NAD+ metabolism, signaling and compartmentalization in the yeast Saccharomyces cerevisiae.

Authors:  Michiko Kato; Su-Ju Lin
Journal:  DNA Repair (Amst)       Date:  2014-08-02

9.  Hyperthermophilic Archaeon Thermococcus kodakarensis Utilizes a Four-Step Pathway for NAD+ Salvage through Nicotinamide Deamination.

Authors:  Shin-Ichi Hachisuka; Takaaki Sato; Haruyuki Atomi
Journal:  J Bacteriol       Date:  2018-05-09       Impact factor: 3.490

Review 10.  Sirtuins and NAD+ in the Development and Treatment of Metabolic and Cardiovascular Diseases.

Authors:  Alice E Kane; David A Sinclair
Journal:  Circ Res       Date:  2018-09-14       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.